I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
H. Kantarjian
477
results:
Search for persons
X
Format
Online (477)
Mediatypes
E-Books (3)
Articles (Online) (234)
Bookchapter (Online) (7)
OpenAccess-fulltext (233)
Sorted by: Relevance
Sorted by: Year
?
1
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III:..:
Savona, M.
;
Mccloskey, J.
;
Griffiths, E.
...
Leukemia Research. 128 (2023) - p. 107271 , 2023
Link:
https://doi.org/10.1016/..
?
2
P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZ..:
Kadia, T.
;
Ravandi, F.
;
Borthakur, G.
...
HemaSphere. 6 (2022) - p. 1080-1081 , 2022
Link:
https://doi.org/10.1097/..
?
3
P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WI..:
Bazinet, A.
;
Jabbour, E.
;
Kantarjian, H.
...
HemaSphere. 6 (2022) - p. 652-653 , 2022
Link:
https://doi.org/10.1097/..
?
4
P707: DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS W..:
Apperley, J.
;
Kantarjian, H.
;
Deininger, M.
...
HemaSphere. 6 (2022) - p. 602-603 , 2022
Link:
https://doi.org/10.1097/..
?
5
P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ..:
Venugopal, S.
;
kantarjian, H.
;
Maiti, A.
...
HemaSphere. 6 (2022) - p. 679-680 , 2022
Link:
https://doi.org/10.1097/..
?
6
S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) ..:
Yilmaz, M.
;
Muftuoglu, M.
;
Kantarjian, H.
...
HemaSphere. 6 (2022) - p. 28-29 , 2022
Link:
https://doi.org/10.1097/..
?
7
S160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER H..:
Montalban-Bravo, G.
;
Ma, F.
;
Ganan-Gomez, I.
...
HemaSphere. 6 (2022) - p. 61-62 , 2022
Link:
https://doi.org/10.1097/..
?
8
P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN..:
Haddad, F.
;
Kantarjian, H.
;
Jabbour, E.
...
HemaSphere. 6 (2022) - p. 598-599 , 2022
Link:
https://doi.org/10.1097/..
?
9
P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS F..:
Masarova, L.
;
Bose, P.
;
Pemmaraju, N.
...
HemaSphere. 6 (2022) - p. 933-934 , 2022
Link:
https://doi.org/10.1097/..
?
10
P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE ..:
Abuasab, T.
;
Senapati, J.
;
Kadia, T.
...
HemaSphere. 6 (2022) - p. 396-397 , 2022
Link:
https://doi.org/10.1097/..
?
11
PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CH..:
Jabbour, E.
;
Martinelli, G.
;
Vignetti, M.
...
HemaSphere. 6 (2022) - p. 1643-1644 , 2022
Link:
https://doi.org/10.1097/..
?
12
PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE M..:
Ong, F.
;
Kadia, T. M.
;
Short, N. J.
...
HemaSphere. 6 (2022) - p. 1711-1712 , 2022
Link:
https://doi.org/10.1097/..
?
13
P1052: IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS:
Senapati, J.
;
Verstovsek, S.
;
Masarova, L.
...
HemaSphere. 6 (2022) - p. 942-943 , 2022
Link:
https://doi.org/10.1097/..
?
14
S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADEL..:
Short, N.
;
Kantarjian, H.
;
Konopleva, M.
...
HemaSphere. 6 (2022) - p. 15-16 , 2022
Link:
https://doi.org/10.1097/..
?
15
P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THE..:
Kim, K.
;
Ong, F.
;
Li, Z.
...
HemaSphere. 6 (2022) - p. 665-666 , 2022
Link:
https://doi.org/10.1097/..
1-15